5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study
Stephen P. Mulligan(Royal North Shore Hospital), Gavin Cull(Sir Charles Gairdner Hospital), Giles Best(Flinders University), Rosemary Harrup(University of Tasmania), Maya Latimer(Georgetown University), Devinder Gill(Princess Alexandra Hospital), David Simpson(North Shore Hospital), William Renwick(The Royal Melbourne Hospital), Melanie Sulda(Flinders Medical Centre), Leanne Berkahn(Auckland City Hospital), Paul Turner(Imperial College London), Bryone J. Kuss(Flinders Medical Centre)
Cited by 2
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
World Allergy Organization Anaphylaxis Guidance 2020
|World Allergy Organization Journal|2020|1.1k
International consensus guidelines for the diagnosis and management of food protein–induced enterocolitis syndrome: Executive summary—Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma & Immunology
|Journal of Allergy and Clinical Immunology|2017|675